Bioray Laboratories: Clinical Trials

28 trials sponsored by Bioray Laboratories, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 unknown, 5 recruiting, 4 completed, 4 suspended. 14 Not applicable, 9 Phase 1, 3 Early Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable14Unknown 5, Suspended 3, Completed 2, Recruiting 2, Enrolling by invitation 1, Withdrawn 1
Phase 19Active not recruiting 2, Completed 2, Unknown 2, Recruiting 1, Suspended 1, Terminated 1
Early Phase 13Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 23Active not recruiting 1, Completed 1, Terminated 1

Follow Bioray Laboratories: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Universal CAR-T Cell Therapy for MM
Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection - Multiple Myeloma, Multiple Myeloma in Relapse
Not applicableRecruitingBioray Laboratories62025-04-102025-12-01
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
PSMA-UCAR T (BRL-302) - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Phase 1Active not recruitingShanghai Changzheng Hospital32025-03-272026-07-23
Universal CAR-T Cell Therapy for NHL
BRL-301 - Non-hodgkin Lymphoma,B Cell
Not applicableRecruitingBioray Laboratories62025-03-112025-11-25
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T - Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized
Early Phase 1Not yet recruitingXuanwu Hospital, Beijing252025-02-282025-01-01
Long-term Follow-up Study of BRL-101 for TDT
Assessments - Thalassemia, Beta
RecruitingBioray Laboratories452024-12-082026-07-21
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
Universal BCMA-CD19 CART - Autoimmune Disease
Phase 1UnknownBioray Laboratories182024-11-252024-11-12
Universal CAR-T Cell Therapy for Refractory Lupus Nephritis
BCMA CART + CD19 CART - Lupus Nephritis
Early Phase 1UnknownBioray Laboratories102024-11-252024-11-08
Clinical Study of BRL-101 in Severe SCD
BRL-101 - Sickle Cell Disease
Not applicableUnknownBioray Laboratories32024-07-292024-07-31
Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease
BRL-101 autologous hematopoietic stem and progenitor cells injection - Sickle Cell Disease
Not applicableUnknownBioray Laboratories12024-06-142024-06-03
Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease
BRL-101 - Sickle Cell Disease
Not applicableUnknownBioray Laboratories52024-04-202024-03-19
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
Enhanced autologous PSMA-CAR T - Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Early Phase 1Active not recruitingShanghai Changzheng Hospital182024-03-032026-07-23
Efficacy and Safety Evaluation of PD1-BCMA-CART
PD1-BCMA-CART - Multiple Myeloma
Not applicableUnknownBioray Laboratories92024-03-012024-01-05
Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells
γ-globin reactivated autologous hematopoietic stem cells - Thalassemia Major
Not applicableSuspendedBioray Laboratories52023-12-252024-02-28
Safety and Efficacy Evaluation of Next-generation CD19-UCART
CD19-UCART - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Phase 1UnknownBioray Laboratories202023-12-202023-01-27
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
BRL-301 - Systemic Lupus Erythematosus (SLE)
Not applicableUnknownBioray Laboratories122023-08-142024-09-27
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
BRL-301 - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Not applicableEnrolling by invitationBioray Laboratories152023-05-172024-11-20
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection - Non-hodgkin Lymphoma,B Cell
Phase 1RecruitingBioray Laboratories182023-04-252025-11-25
Long-term Follow-up Study of BHC001 for TDT
Assessments - Thalassemia, Beta
RecruitingBioray Laboratories62022-12-142024-03-18
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
BRL-101 - Beta-Thalassemia
Phase 1 / Phase 2Active not recruitingBioray Laboratories392022-11-022026-07-21
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
PD1-PSMA-CART cells - Castrate-Resistant Prostate Cancer
Phase 1CompletedZhejiang University32021-12-232023-07-17

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Multiple Myeloma (4)  ·  beta-Thalassemia (4)  ·  Anemia, Sickle Cell (3)  ·  Lupus Erythematosus, Systemic (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Antiphospholipid Syndrome (1)  ·  Autoimmune Diseases (1)  ·  Lupus Nephritis (1)  ·  Lymphoma, B-Cell (1)  ·  Multiple Sclerosis (1)  ·  Myasthenia Gravis (1)  ·  Myositis (1)  ·  Neoplasm Metastasis (1)  ·  Neuromyelitis Optica (1)

Countries

China (23)

Top investigators

Rongmei Liang, PhD (2)  ·  Yi Zhang, Professor (2)  ·  Yunxiao Xu, MD (2)  ·  Aibin Liang, PhD (1)  ·  Bin Fu, Prof. (1)  ·  He Huang, Prof (1)  ·  He Huang, Professor (1)  ·  Ping Li, PhD (1)  ·  Shancheng Ren, MD, PhD (1)  ·  Shancheng Ren, Professor (1)  ·  Wei Li (1)  ·  Weijia Fang, MD (1)  ·  Xiaochen Wang, PhD (1)  ·  Xiaohui Wang, PhD (1)

Results publications

PMID 34175041, PMID 35468680, PMID 35922667, PMID 36045296, PMID 37192741, PMID 37251628, PMID 39013470, PMID 40446794